Boosting BCG Vaccination with MVA85A Reduces TGF-β1 Levels
Author Information
Author(s): Helen A. Fletcher, Ansar A. Pathan, Tamara K. Berthoud, Susanna J. Dunachie, Kathryn T. Whelan, Nicola C. Alder, Clare R. Sander, Adrian V.S. Hill, Helen McShane
Primary Institution: Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford
Hypothesis
Does boosting BCG vaccination with MVA85A affect TGF-β1 levels and T cell responses?
Conclusion
Boosting BCG vaccination with MVA85A significantly reduces TGF-β1 levels and enhances immune responses in BCG-primed subjects.
Supporting Evidence
- MVA85A vaccination reduces TGF-β1 mRNA in peripheral blood lymphocytes.
- TGF-β1 protein levels decreased significantly after vaccination.
- Enhanced IFN-γ responses to recall antigens were observed in BCG-primed subjects.
Takeaway
This study shows that giving a second vaccine after the first one can help the body fight infections better by lowering a certain protein that can weaken the immune response.
Methodology
The study involved clinical trials with BCG-primed and naïve subjects, measuring TGF-β1 mRNA and protein levels before and after vaccination with MVA85A.
Potential Biases
Potential bias due to the small number of subjects and the specific population studied.
Limitations
The study had a small sample size and focused only on specific immune responses.
Participant Demographics
Subjects were aged 18–55, seronegative for HIV, HBV, and HCV.
Statistical Information
P-Value
0.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website